Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 3, 2012, Pages 686-696

  Mohajer, Kiyarash ^a   Frydrychowicz, Alex ^a,b   Robbins, Jessica B ^a   Loeffler, Agnes G ^c   Reed, Thomas D ^a   Reeder, Scott B ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d University of Wisconsin Madison   (United States)

Author keywords

FNH; focal nodular hyperplasia; gadoxetic acid; hepatic adenoma; magnetic resonance imaging

Indexed keywords

GADOXETIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HEPATOBILIARY RADIOGRAPHY; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER ADENOMA; LIVER FOCAL NODULAR HYPERPLASIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING;

ADENOMA; ADULT; CONTRAST MEDIA; FEMALE; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84865331122     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23701     Document Type: Article

References (30)

1. Lizardi-Cervera J, Cuellar-Gamboa L, Motola-Kuba D,. Focal nodular hyperplasia and hepatic adenoma: a review. Ann Hepatol 2006; 5: 206-211. (Pubitemid 44435365)
2. Maillette de Buy Wenniger L, Terpstra V, Beuers U,. Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 2010; 27: 24-31.
3. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009; 16: 640-648.
4. Farges O, Dokmak S,. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg 2010; 27: 32-38.
5. Grazioli L, Morana G, Kirchin MA, Schneider G,. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-177. (Pubitemid 40853309)
6. Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C,. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999; 23 (12): 1441-1454.
7. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A,. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21: 877-892; discussion 892-894.
8. Morana G, Grazioli L, Kirchin MA, et al. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011; 46: 225-239.
9. Kirchin MA, Pirovano GP, Spinazzi A,. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998; 33: 798-809.
10. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
11. Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann HP,. MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol 2008; 190: W290-W293. (Pubitemid 351684910)
12. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. (Pubitemid 40139918)
13. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO,. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43: 504-511.
14. Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N,. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 2009; 50: 709-715.
15. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2010; 46: 141-145.
16. Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM,. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. AJR Am J Roentgenol 2011; 196: W18-W24.
17. Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology 1999; 212: 876-884. (Pubitemid 29410996)
18. Nagle SN, Busse RF, Brau AC, et al. High-resolution free-breathing 3D T1 weighted hepatobiliary imaging optimized for Gd-EOB-DTPA. Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, Hawaii, 2009. (abstract 2076).
19. Frydrychowicz A, Nagle SN, D'souza SL, Vigen KK, Reeder SB,. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3T: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging. 2011 Jul 12. doi:10.1002/jmri.22713. [Epub ahead of print].
20. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985; 89: 1132-1138. (Pubitemid 16231581)
21. Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S,. Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium. J Magn Reson Imaging 2010; 32: 341-344.
22. Wanless IR, Mawdsley C, Adams R,. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5: 1194-1200. (Pubitemid 16222291)
23. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007; 46: 521-527. (Pubitemid 46201719)
24. Vander Borght S, Libbrecht L, Blokzijl H, et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 2005; 207: 471-482. (Pubitemid 43025696)
25. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE,. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-157. (Pubitemid 29302315)
26. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356-364.
27. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging-correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-826.
28. Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011; 21: 2056-2066.
29. Hussain SM,. Liver MRI: correlation with other imaging modalities and histopathology. Heidelberg: Springer Verlag; 2007. p 132-133.
30. Hussain SM,. Liver MRI: correlation with other imaging modalities and histopathology. Heidelberg, Germany: Springer Verlag; 2007. p 116-117.